23 May 2024 - Bausch Health today announced additional Canadian public drug plan listings for Uceris (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.

Uceris has most recently become available for patients through the public drug plans of Alberta, Prince Edward Island and Newfoundland and Labrador, as well as to beneficiaries of the federal drug plans for Indigenous people through the Non-Insured Health Benefit and Veterans Affairs Canada.

Earlier this year, Uceris was made available for patients through the public drug plans of Ontario, Quebec, Saskatchewan, New Brunswick and Nova Scotia.

Read Bausch Health press release